Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
In-Vivo Evaluation of Dt386-Br2, a Promising Anticancer Fusion Protein, in Mice Model



Shafiee F1 ; Enteshari R2 ; Rabbani M1 ; Jahaniannajafabadi A3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Science, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Pharmaceutical Biotechnology AND Bioinformatics Research Center, School Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2017

Abstract

Background: Cancer is one of the greatest health-related problems and due to increasing drug resistance and severe side effects of chemotherapeutic agents, production of targeted anticancer agents with lower side effects is under consideration. Previously, we produced a fusion protein consisted of catalytic and translocation domains of diphtheria toxin (DT386) fused to BR2, a cancer specific cell penetrating peptide. First steps of this study showed selective antiproliferative effects of DT386-BR2 on cancer cells but not on normal cell lines. The aim of the present study was evaluation of its in-vivo non-specific toxicity in healthy mice. Methods: The fusion protein was produced and purified through recombinant DNA technology. Intraperitoneal injections with various concentrations of DT386-BR2 were done in healthy mice for five consecutive days and they observed for 14 days after the last injection inspecting their food consumption, body weight, body temperature, and finally being dead or alive. Negative controls were injected with normal saline solution. Findings: There was not any significant effect on temperature, body weight, and viability of mice received various concentrations of DT386-BR2 (P < 0.05), and increasing the protein concentration did not show any adverse effects on mice. Conclusion: DT386-BR2 can be used for further pre-clinical studies to determine its pharmacokinetics/pharmacodynamics profiles and evaluation of its anticancer efficacy in suitable xenograft animal models. © 2017, Isfahan University of Medical Sciences(IUMS). All rights reserved.
Other Related Docs
9. Application of Antimicrobial Peptides in the Design and Production of Anticancer Agents, International Journal of Peptide Research and Therapeutics (2023)
11. Cloning, Expression, and Assessment of Cytotoxic Effects of A-Ngr Fusion Protein, International Journal of Peptide Research and Therapeutics (2018)
12. Anti-Tumor Effects of Recombinant Clostridium Α-Toxin on Breast Cancer: An in Vitro and in Vivo Study, International Journal of Molecular and Cellular Medicine (2024)